HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): John S. Ikonomidis Robert E. Stroud Fred A. Crawford, Jr Francis G. Spinale Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ikonomidis, J. S. Articles by Spinale, F. G. Search for Related Content PubMed PubMed Citation Articles by Ikonomidis, J. S. Articles by Spinale, F. G. Related Collections Cardiac - pharmacology

Ann Thorac Surg 2007;83:2153-2161
© 2007 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

Selective Endothelin-A Receptor Inhibition After Cardiac Surgery: A Safety and Feasibility Study

Division of Cardiothoracic Surgery, Cardiothoracic Surgical Laboratory, Medical University of South Carolina, and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina

Accepted for publication February 26, 2007.

^_* Address correspondence to Dr Ikonomidis, Division of Cardiothoracic Surgery, Medical University of South Carolina, Suite 409CSB, 96 Jonathan Lucas St, Charleston, SC 29425. (Email: ikonomij{at}musc.edu).

Presented at the Fifty-third Annual Meeting of the Southern Thoracic Surgical Association, Tucson, AZ, Nov 8–11, 2006.

Background: Increased synthesis and release of the bioactive peptide endothelin has been shown to change hemodynamics and postoperative recovery after cardiac surgery. However, the clinical effects of selective interruption of endothelin signaling have not been studied. Because the endothelin-A (ET-A) receptor subtype is the primary cardiovascular effector for endothelin, this study used the ET-A receptor antagonist sitaxsentan sodium (TBC11251Na) to evaluate: (1) dose-dependent changes in pulmonary artery pressure (PAP) and pulmonary (PVRI) and systemic (SVRI) vascular resistance index in patients undergoing on-pump coronary revascularization; and (2) whether ET-RA administration was associated with increased adverse events.

Methods: Patients (n = 44, age, 62 ± 1 years) were randomized to receive vehicle (n = 9) or different bolus infusions of ET-A receptor antagonist: 0.1 (n = 9), 0.5 (n = 9) 1.0 (n = 9), and 2.0 mg/kg (n = 8) at separation from cardiopulmonary bypass (CPB). Adverse events were tabulated until hospital discharge. Results were expressed as changes from a composite baseline value, or from time 0 due to a high degree of intrapatient measurement variability in the postoperative period.

Results: PAP increased by 27% ± 13% from baseline (19 ± 1 mm Hg) in the vehicle group at 6 hours post-CPB (p < 0.05). PAP fell from this post-CPB vehicle value in a dose-dependent manner with the ET-A receptor antagonist; with a significant reduction observed at 2 mg/kg (7% ± 8% increase from baseline, p < 0.05). PVRI was reduced by 28.6% ± 16% from baseline (249 ± 22 dyn · s · cm^–5 · m^–2) in the 2 mg/kg ET-A receptor antagonist group at 30 minutes post-CPB and remained reduced up to 6 hours post-CPB (p < 0.05). SVRI was reduced from baseline (2770 ± 106 dyn · s · cm^–5 · m^–2) by 51% ± 6% in the 2.0 mg/kg ET-A receptor antagonist group at 30 minutes post-CPB (p < 0.05) and remained reduced up to 6 hours post-CPB. A total of 203 adverse events were tabulated in the postoperative period and were equally distributed across the five treatment groups, with no direct attributions to ET-A receptor antagonist treatment.

Conclusions: This unique study demonstrates that heightened endothelin-A receptor activation contributes to hemodynamic changes in patients after CPB. Selective inhibition of the endothelin receptor system can be successfully and safely performed in patients undergoing cardiac surgery and thereby reveals a potential, and clinically relevant therapeutic target.

This article has been cited by other articles:

				J.-B. Huang, J. Liang, and L.-Y. Zhou Eisenmenger Syndrome: Not Always Inoperable Respir Care, September 1, 2012; 57(9): 1488 - 1495. [Abstract] [Full Text] [PDF]

				J. M. Toole, J. S. Ikonomidis, W. Y. Szeto, J. L. Zellner, J. Mulcahy, R. L. Deardorff, and F. G. Spinale Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics J. Thorac. Cardiovasc. Surg., March 1, 2010; 139(3): 646 - 654. [Abstract] [Full Text] [PDF]

				R. L. Ford, I. M. Mains, E. J. Hilton, S. T. Reeves, R. E. Stroud, F. A. Crawford Jr, J. S. Ikonomidis, and F. G. Spinale Endothelin-A Receptor Inhibition After Cardiopulmonary Bypass: Cytokines and Receptor Activation Ann. Thorac. Surg., November 1, 2008; 86(5): 1576 - 1583. [Abstract] [Full Text] [PDF]